Our research findings indicated a slightly lower incidence of all-grade CEs in early-stage breast cancer compared to advanced/metastatic cases (3.7% versus 5.8%), although this difference did not reach statistical significance ( p =0.093).
← all excerpts
Incidence of HER2-targeted antibody-drug conjugates-related cardiac events: a meta-analysis.
1
0.0930
0.0930